Build Fast Formula, LLC – Trademark Portfolio

Entity Type: 16

Build Fast Formula, LLC holds 11 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 11 filings in this category. The portfolio also extends into Class 25 (Clothing) across 2 Nice Classification classes. Currently, 3 trademarks are registered and 1 is pending. Notable registered marks include BLITZ3D, DRINKHACK, and EIGHTY:20. The owner is based in Dallas, TX.

3737 Atwell Street, #107

Dallas, TX 75209

11 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Build Fast Formula, LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (11 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

25
Clothing (3 filings)

Clothing, footwear, headgear

Frequently Asked Questions

How many trademarks does Build Fast Formula, LLC have?

Build Fast Formula, LLC has 11 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 pending, 4 abandoned, 3 cancelled.

What trademark classes does Build Fast Formula, LLC file in?

Build Fast Formula, LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 25 (Clothing). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Build Fast Formula, LLC's most well-known trademarks?

Build Fast Formula, LLC's registered trademark portfolio includes well-known marks such as BLITZ3D, DRINKHACK, and EIGHTY:20. These are among 3 currently registered trademarks in the portfolio.

What is Build Fast Formula, LLC's trademark registration success rate?

Build Fast Formula, LLC has a 30% trademark registration rate, with 3 out of 10 resolved applications resulting in successful registration. Currently, 1 application is pending review.